Molecure S.A. (WSE: MOC)

Market Cap	232.34M
Revenue (ttm)	1.93M
Net Income (ttm)	-29.33M
Shares Out	16.84M
EPS (ttm)	-1.68
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	9,500
Open	13.30
Previous Close	13.48
Day's Range	13.22 - 13.88
52-Week Range	13.12 - 22.50
Beta	2.21
Analysts	n/a
Price Target	n/a
Earnings Date	Sep 6, 2024

About Molecure

Molecure S.A., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for the treatment of neoplastic and inflammatory diseases in Poland. The company is involved in the development of OATD-01, a chitotriosidase/AMCASE inhibitor that has completed phase I clinical trial for the treatment of sarcoidosis, as well as in preclinical stage to treat idiopathic pulmonary fibrosis and NASH. It also develops OATD-02, an arginase 1 and arginase 2, which is in Phase I clinical trial for the treatment of c...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2012
• Employees: 111
• Stock Exchange: Warsaw Stock Exchange
• Ticker Symbol: MOC

Financial Performance

In 2023, Molecure's revenue was 3.65 million, a decrease of -51.39% compared to the previous year's 7.51 million. Losses were -28.37 million, -21.08% less than in 2022.